Insys Therapeutics, Inc. (INSY) today announced that the U.S. Food and Drug Administration (FDA) has approved Insys' dronabinol oral solution, SyndrosTM, an orally administered liquid formulation of the pharmaceutical cannabinoid dronabinol, a pharmaceutical version of tetrahydrocannabinol ("THC"). Syndros is currently awaiting scheduling by the U.S. DEA...
Read more
FDA Approves Synthetic Liquid Marijuana Compound
